Shots:

• The P-III DAPA-CKD involve assessing of Farxiga ((dapagliflozin- 10mg- qd) + SOC vs PBO in 4-304 patients with CKD Stages 2–4 and elevated urinary albumin excretion- with and without T2D
• The study met its 1EPs i.e. worsening of renal function or risk of death (defined as a composite of an eGFR decline ≥50%- the onset of ESKD and death from CV/ renal cause) and 2EPs i.e. time to first occurrence of the renal composite (sustained ≥50% eGFR decline- ESKD- and renal death
• Farxiga (PO- qd) is an SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monothx. and combination therapy as an adjunct to diet and exercise to improve glycemic control- weight loss and BP reduction

­ Ref: AstraZeneca | Image: Bloomberg Quint